ⅠB期非小细胞肺癌术后辅助化疗的争议和共识

临床上有20％～25％的非小细胞肺癌（NSCLC）患者可手术治疗，但5年生存率也只有40％左右。辅助化疗是部分早期可切除肺癌的标准治疗方式，可使4％～15％的患者生存获益。但是，ⅠB期NSCLC是否能从辅助化疗中获益仍存在争议。近年来，多个临床研究评价了ⅠB期NSCLC辅助化疗的疗效，我们通过分析这些临床研究，寻找ⅠB期NSCLC的高危人群和辅助化疗的适应证。

Adjuvant chemotherapy in patients with stage I B non-small cell lung cancer

Although surgery is regarded as the best possible treatment for patients with early stage non-small cell lung cancer （ NSCLC ）, only 20% -25% of patients have resectable disease at presentation. Despite optimal surgical treatment, 5-year survival rates in patients with resectable NSCLC are historically modest（40% ）. Adjuvant chemotherapy has been a standard treatment after complete resection in early stage NSCLC,and 4%-15% patients can benefit from it. In recent years, although multiple randomized trials assess- ing the efficacy of adjuvant chemotherapy for stage I B NSCLC have been reported, the benefit of adjuvant chemotherapy in patients with stage I B NSCLC is controversial. Herein, we review the results of the major adjuvant chemotherapy trials and find the high-risk patients and their implications for the treatment of stage I B NSCLC.